BioSpace47m
FDA Faces ‘Catastrophic Collapse’ as Massive Layoffs Endanger User Fee Program
The FDA derives just under half of its yearly funding from pharma user fees, which help support its operations and fund ...
BioSpace1h
Amgen Wins Expansion for Uplizna as First Drug for IgG4-Related Disease
The FDA approved Amgen ’s anti-CD19 therapy Uplizna Thursday for use in patients with IgG4-related disease. Uplizna is the ...
BioSpace1h
Lilly Throws Sangamo a Lifeline with Pact Worth Potential $1.4B+
Sangamo, which has been having cash problems, will receive $18 million upfront in licensing fees for its AAV capsid that has ...
BioSpace18h
FDA Layoffs Continue as Former Commissioner Robert Califf Speaks Out
The latest cuts, which are part of a larger reduction of 10,000 at the Department of Health and Human Services, were ...
BioSpace23h
Sarepta’s Duchenne Gene Therapy Placed on Hold in Europe Pending Death Investigation
The European Medicines Agency asked for three clinical trials to be placed on hold until the exact cause of death of a US ...